Dose Dependent Synergism from Combination of Platinum Drugs with Curcumin against Colorectal Cancer Cell Lines
Dose Dependent Synergism from Combination of Platinum Drugs with Curcumin against Colorectal Cancer Cell Lines
Hana Bali1, Jun Qing Yu1, Philip Beale2, and Fazlul Huq3
Journal of Angiotherapy 4(1) https://doi.org/10.25163/angiotherapy.41210611810120920
Submitted: 18 August 2020 Revised: 04 September 2020 Published: 12 September 2020
Introduction: Colorectal cancer is the fourth most common cause of cancer mortality. More than 41265 new cases of colorectal cancer were detected and around 15903 colorectal cancer deaths occurred in year 2014 worldwide according to the statistical study from the cancer research. Chemotherapy is still in the main stream of the management of colorectal cancer along with surgery and radiotherapy. Aim: The objective of the present study was to investigate the activity of curcumin in combination with platinum drugs against colorectal cancer models (HT-29, Caco-2, LIM-1215 and LIM-2405). Methods: IC50 values of cisplatin (Cs) , oxaliplatin (Ox), and curcumin (Cur) were determined against four human colorectal cancer cell lines using MTT reduction assay. Combined drug activity was determined as a factor of sequence of administration (0/0, 0/4 and 4/0 h) and added concentrations. DNA binding and proteomics were carried out to obtain insight into molecular mechanisms of drug action. Results: Oxaliplatin in combination with curcumin produced strong synergism in the tested cell lines. Cellular accumulation study, platinum-DNA binding study and DNA damage study revealed the mechanism of combined drug affects. Upregulation of K1C18, GRP78, IDHC and Cofilin-1 proteins was considered to be associated with the synergistic combined effects of oxaliplatin with curcumin. Conclusion: Ox in combination Cur demonstrated very high synergism against HT-29 and Caco-2 cell lines. Synergism from Ox with Cur may beassociated with greater platinum-DNA binding. Proteomics revealed that the elevated expressions of K1C18, GRP78, IDHC and Cofilin1 may be responsible for the synergistic activity obtained from the combination of Ox with Cur.
Al-Eisawi, Z., P. Beale, et al. (2013). "Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models." Journal of ovarian research 6(1), 78.
Al-Eisawi, Z., P. Beale, et al. (2016). "Changes in the in vitro activity of platinum drugs when administered in two aliquots." BMC cancer 16(1), 688.
Alam, M. N., J. Q. Yu, et al. (2020). "Cisplatin in combination with emetine and patulin showed dose and sequence dependent synergism against ovarian cancer." Synergy 10, 100060.
Alam, M. N., J. Q. Yu, et al. (2020). "Dose and sequence dependent synergism from the combination of oxaliplatin with emetine and patulin against colorectal cancer." Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 20(2), 264-273.
Arzuman, L., P. Beale, et al. (2016). "Synthesis of tris (quinoline) monochloroplatinum (II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines." Anticancer research 36(6), 2809-2818.
Bernstein, B. W. and J. R. Bamburg (2010). "ADF/cofilin: a functional node in cell biology." Trends in cell biology 20(4), 187-195.
Björklund, B. (1978). Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Laboratory testing for cancer, Karger Publishers. 22, 16-31.
Björklund, B. and V. Björklund (1957). "Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heat-labile tumor antigen." International Archives of Allergy and Immunology 10(3), 153-184.
Buddaseth, S., W. Göttmann, et al. (2013). "Dysregulation of cell cycle control caused by overexpression of the oncogene pp32r1 (ANP32C) and the Tyr> His mutant pp32r1Y140H." Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1833(5), 1212-1221.
Bühler, H. and G. Schaller (2005). "Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo." Molecular cancer research 3(7), 365-371.
Calvert, A. E. (2017). Cancer-Associated Isocitrate Dehydrogenase 1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation, Northwestern University.
Canelle, L., J. Bousquet, et al. (2006). "A proteomic approach to investigate potential biomarkers directed against membrane-associated breast cancer proteins." Electrophoresis 27(8), 1609-1616.
Caulin, C., C. F. Ware, et al. (2000). "Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis." The Journal of cell biology 149(1), 17-22.
Chou, T.-C. and P. Talalay (1984). "Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors." Advances in enzyme regulation 22, 27-55.
Chua, B. T., C. Volbracht, et al. (2003). "Mitochondrial translocation of cofilin is an early step in apoptosis induction." Nature cell biology 5(12), 1083.
Daneshmand, S., M. L. Quek, et al. (2007). "Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival." Human pathology 38(10), 1547-1552.
Davalieva, K., I. M. Kostovska, et al. (2015). "Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer." The Prostate 75(14), 1586-1600.
Dhara, S. (1970). "Cisplatin." Indian J. Chem 8:,123-134.
Fang, H., S. Chen, et al. (2011). "Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells." Phytomedicine 18(8-9), 697-703.
Ferlay, J., I. Soerjomataram, et al. (2015). "GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. 2014." Available from: globocan. iarc. fr.
Frankland-Searby, S. and S. R. Bhaumik (2012). "The 26S proteasome complex: an attractive target for cancer therapy." Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1825(1), 64-76.
Fu, Y. and A. S. Lee (2006). "Glucose regulated proteins in cancer progression, drug resistance and immunotherapy." Cancer biology & therapy 5(7), 741-744.
Ghosh, M., X. Song, et al. (2004). "Cofilin promotes actin polymerization and defines the direction of cell motility." Science 304(5671), 743-746.
Hamler, R. L., K. Zhu, et al. (2004). "A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification." Proteomics 4(3), 562-577.
Han, L., M. B. Stope, et al. (2007). "Direct stimulation of receptor-controlled phospholipase D1 by phospho-cofilin." The EMBO journal 26(19), 4189-4202.
Hmmier, A., M. E. O'Brien, et al. (2017). "Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry." BBA clinical 7, 97-104.
Holch, J. W., I. Ricard, et al. (2017). "The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials." European Journal of Cancer 70, 87-98.
Howells, L. M., S. Sale, et al. (2011). "Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo." International journal of cancer 129(2), 476-486.
Huq, F. (2015). Synergism from combination of targeted therapy with tumor active phytochemicals in ovarian tumor models and changes in protein expression, AACR.
Huq, F., J. Q. Yu, et al. (2014). "Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer." Anticancer research 34(1), 541-545.
Kang, J. H., H. S. Kang, et al. (2015). "Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin." Experimental Biology and Medicine 240(11), 1416-1425.
Keshamouni, V. G., G. Michailidis, et al. (2006). "Differential protein expression profiling by iTRAQ− 2DLC− MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype." Journal of proteome research 5(5), 1143-1154.
Ku, N. O., R. M. Soetikno, et al. (2003). "Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury." Hepatology 37(5), 1006-1014.
Kubota, H., S. Yamamoto, et al. (2010). "Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma." Cell Stress and Chaperones 15(6), 1003-1011.
Lai, K. K., K. T. Chan, et al. (2016). "14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules." Tumor Biology 37(2), 2127-2136.
Larcher, F., C. Bauluz, et al. (1992). "Aberrant expression of the simple epithelial type II keratin 8 by mouse skin carcinomas but not papillomas." Molecular carcinogenesis 6(2), 112-121.
Lee, A. S. (2007). "GRP78 induction in cancer: therapeutic and prognostic implications." Cancer research 67(8), 3496-3499.
Lee, E., P. Nichols, et al. (2006). "GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer." Cancer research 66(16), 7849-7853.
Lei, T., X. Zhao, et al. (2013). "Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis." Clinical genitourinary cancer 11(1), 56-62.
Levis, M., R. Pham, et al. (2004). "In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects." Blood 104(4), 1145-1150.
Li, L., B. Ahmed, et al. (2007). "Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer." Molecular cancer therapeutics 6(4), 1276-1282.
Lu, D., T. Lu, et al. (2013). "Drug combinations in cancer treatment." Clinical Experimental Pharmacology 3(4), 134.
Lu, Z., Q. Song, et al. (2014). "Comparative proteomic analysis of anti-cancer mechanism by periplocin treatment in lung cancer cells." Cellular Physiology and Biochemistry 33(3), 859-868.
Macias, A. T., D. S. Williamson, et al. (2011). "Adenosine-derived inhibitors of 78 kDa glucose regulated protein (Grp78) ATPase: insights into isoform selectivity." Journal of medicinal chemistry 54(12), 4034-4041.
Maeda, A., H. Ohguro, et al. (2000). "Aberrant expression of photoreceptor-specific calcium-binding protein (recoverin) in cancer cell lines." Cancer Research 60(7), 1914-1920.
Magin, T. M., P. Vijayaraj, et al. (2007). "Structural and regulatory functions of keratins." Experimental cell research 313(10), 2021-2032.
Martoglio, A.-M., B. Tom, et al. (2000). "Changes in tumorigenesis-and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays." Molecular Medicine 6(9), 750.
Mazumder, M. E. H., P. Beale, et al. (2012). "Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells." Anticancer research 32(11), 4851-4860.
Miyake, H., I. Hara, et al. (2000). "Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells." Journal of cellular biochemistry 77(3), 396-408.
Moll, R., M. Divo, et al. (2008). "The human keratins: biology and pathology." Histochemistry and cell biology 129(6), 705.
Montopoli, M., E. Ragazzi, et al. (2009). "Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells." Cell proliferation 42(2), 195-206.
Mosmann, T. (1983). "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays." Journal of immunological methods 65(1-2), 55-63.
Nautiyal, J., S. S. Kanwar, et al. (2011). "Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells." Journal of molecular signaling 6(1), 7.
Nebl, G., S. C. Meuer, et al. (1996). "Dephosphorylation of serine 3 regulates nuclear translocation of cofilin." Journal of Biological Chemistry 271(42), 26276-26280.
Nessa, M. U., P. Beale, et al. (2012). "Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells." Anticancer research 32(1), 53-59.
Nessa, M. U., P. Beale, et al. (2012). "Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models." Anticancer research 32(11), 4843-4850.
O'Connell, K., M. Prencipe, et al. (2012). "The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines." Proteomics 12(13), 2115-2126.
Onda, M., M. Emi, et al. (2004). "Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes." Endocrine-related cancer 11(4), 843-854.
Qi, Y., J. F. Chiu, et al. (2005). "Comparative proteomic analysis of esophageal squamous cell carcinoma." Proteomics 5(11), 2960-2971.
Reitman, Z. J. and H. Yan (2010). "Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism." Journal of the National Cancer Institute 102(13), 932-941.
Roblick, U., D. Hirschberg, et al. (2004). "Sequential proteome alterations during genesis and progression of colon cancer." Cellular and Molecular Life Sciences CMLS 61(10), 1246-1255.
Rufino-Palomares, E. E., F. J. Reyes-Zurita, et al. (2013). "Maslinic acid, a triterpenic anti-tumoural agent, interferes with cytoskeleton protein expression in HT29 human colon-cancer cells." Journal of proteomics 83, 15-25.
Russell Hilt, J., W. D. R. Wittliff, et al. (1973). "Studies on Certain Cytoplasmic Enzymes and Specific Estrogen Receptors in Human Breast Cancer and in Nonmalignant Diseases of the Breast1." CANCER RESEARCH 33, 2054-2062.
Sandoval, J. A., D. J. Hoelz, et al. (2006). "Novel peptides secreted from human neuroblastoma: useful clinical tools?" Journal of pediatric surgery 41(1), 245-251.
Schaller, G., I. Fuchs, et al. (1996). "Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer." Clinical Cancer Research 2(11), 1879-1885.
Shishkin, S., L. Eremina, et al. (2016). "Cofilin-1 and other ADF/cofilin superfamily members in human malignant cells." International journal of molecular sciences 18(1), 10.
Shuda, M., N. Kondoh, et al. (2003). "Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis." Journal of hepatology 38(5), 605-614.
Sinha, P., G. Hütter, et al. (1999). "Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-σ (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas." Electrophoresis 20(14), 2952-2960.
Srisomsap, C., P. Sawangareetrakul, et al. (2004). "Proteomic analysis of cholangiocarcinoma cell line." Proteomics 4(4), 1135-1144.
Stellwagen, N. C. (1998). DNA Gel Electrophoresis. Nucleic Acid Electrophoresis. D. Tietz. Berlin, Heidelberg, Springer Berlin Heidelberg: 1-53.
Stricher, F., C. Macri, et al. (2013). "HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting." Autophagy 9(12), 1937-1954.
Takegoshi, K., E. Okada, et al. (2016). "Hepatocellular carcinoma and type 2 diabets mellitus: cytokeratin 8/18 expression in hepatocellular carcinoma and glycogen-storing hepatocytes." Hepatoma Res 2, 229-230.
Tan, F., Y. Jiang, et al. (2012). "Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis." Molecular & Cellular Proteomics 11(2), M111. 008821.
Tsai, C.-H., S.-J. Chiu, et al. (2009). "Regulated expression of cofilin and the consequent regulation of p27kip1 are essential for G1 phase progression." Cell cycle 8(15), 2365-2374.
Tsai, C.-H., L.-T. Lin, et al. (2015). "Over-expression of cofilin-1 suppressed growth and invasion of cancer cells is associated with up-regulation of let-7 microRNA." Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852(5), 851-861.
Turhani, D., K. Krapfenbauer, et al. (2006). "Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis." Electrophoresis 27(7), 1417-1423.
Ueno, T., M. Toi, et al. (2005). "Detection of epithelial cell death in the body by cytokeratin 18 measurement." Biomedicine & pharmacotherapy 59, S359-S362.
Unwin, R. D., R. A. Craven, et al. (2003). "Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect." Proteomics 3(8), 1620-1632.
Vergara, D., P. Simeone, et al. (2013). "Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature." Molecular BioSystems 9(6), 1127-1138.
Wang, H., M. T. Kachman, et al. (2004). "Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers." Proteomics 4(8), 2476-2495.
Wang, J., L. Xu, et al. (2013). "Proteomic analysis reveals that proteasome subunit beta 6 is involved in hypoxia-induced pulmonary vascular remodeling in rats." PloS one 8(7), e67942.
Wang, M., S. Wey, et al. (2009). "Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders." Antioxidants & redox signaling 11(9), 2307-2316.
Willett, W. C. and D. Trichopoulos (1996). "Nutrition and cancer: A summary of the evidence." Cancer Causes and Control 7(1), 178-180.
Wu, S. L., W. S. Hancock, et al. (2003). "An approach to the proteomic analysis of a breast cancer cell line (SKBR-3)." Proteomics 3(6), 1037-1046.
Xiao, B., X. Si, et al. (2015). "Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy." Journal of Materials Chemistry B 3(39), 7724-7733.
Xu, S.-G., P.-J. Yan, et al. (2010). "Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis." Journal of cancer research and clinical oncology 136(10), 1545-1556.
Yamamoto, T., M. Kudo, et al. (2016). "Identification of aldolase A as a potential diagnostic biomarker for colorectal cancer based on proteomic analysis using formalin-fixed paraffin-embedded tissue." Tumor Biology 37(10), 13595-13606.
Yang, M., M. Ren, et al. (2016). "Sulforaphene inhibits hepatocellular carcinoma through repressing keratin 8 and activating anoikis." RSC Advances 6(74), 70326-70334.
Yao, Y., X.-Y. Jia, et al. (2009). "Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment." Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1794(10), 1433-1440.
Yu, T., Y. Yang, et al. (2015). "Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound." European Journal of Pharmaceutics and Biopharmaceutics 91, 103-110.
Yunos, N. M., P. Beale, et al. (2011). "Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells." Anticancer Research 31(4), 1131-1140.
Zhao, L., L. Liu, et al. (2007). "Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins." Journal of cancer research and clinical oncology 133(10), 771-782.
Zhu, S., V. Shanbhag, et al. (2017). "A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance." Journal of Cancer 8(11), 1952.